Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.
Identifieur interne : 000574 ( Main/Exploration ); précédent : 000573; suivant : 000575Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.
Auteurs : Joan Puig-Barberà [Espagne] ; Javier Díez-Domingo ; Angel Belenguer Varea ; Germán Schwarz Chavarri ; José A Lluch Rodrigo ; Santiago Pérez Hoyos ; David González VidalSource :
- Vaccine [ 0264-410X ] ; 2007.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Angiopathies intracrâniennes (prévention et contrôle), Angiopathies intracrâniennes (épidémiologie), Espagne (épidémiologie), Facteurs de risque (MeSH), Hospitalisation (MeSH), Humains (MeSH), Maladies cardiovasculaires (prévention et contrôle), Maladies cardiovasculaires (épidémiologie), Pneumopathie infectieuse (prévention et contrôle), Pneumopathie infectieuse (épidémiologie), Polysorbates (administration et posologie), Squalène (administration et posologie), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Vaccination de masse (statistiques et données numériques), Vaccins antigrippaux (administration et posologie), Vaccins sous-unitaires (administration et posologie), Études cas-témoins (MeSH).
- MESH :
- administration et posologie : Adjuvants immunologiques, Polysorbates, Squalène, Vaccins antigrippaux, Vaccins sous-unitaires.
- prévention et contrôle : Angiopathies intracrâniennes, Maladies cardiovasculaires, Pneumopathie infectieuse.
- statistiques et données numériques : Vaccination de masse.
- épidémiologie : Angiopathies intracrâniennes, Espagne, Maladies cardiovasculaires, Pneumopathie infectieuse.
- Facteurs de risque, Hospitalisation, Humains, Sujet âgé, Sujet âgé de 80 ans ou plus, Études cas-témoins.
- Wicri :
- geographic : Espagne.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Aged (MeSH), Aged, 80 and over (MeSH), Cardiovascular Diseases (epidemiology), Cardiovascular Diseases (prevention & control), Case-Control Studies (MeSH), Cerebrovascular Disorders (epidemiology), Cerebrovascular Disorders (prevention & control), Hospitalization (MeSH), Humans (MeSH), Influenza Vaccines (administration & dosage), Mass Vaccination (statistics & numerical data), Pneumonia (epidemiology), Pneumonia (prevention & control), Polysorbates (administration & dosage), Risk Factors (MeSH), Spain (epidemiology), Squalene (administration & dosage), Vaccines, Subunit (administration & dosage).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Influenza Vaccines, Polysorbates, Squalene, Vaccines, Subunit.
- geographic , epidemiology : Spain.
- epidemiology : Cardiovascular Diseases, Cerebrovascular Disorders, Pneumonia.
- prevention & control : Cardiovascular Diseases, Cerebrovascular Disorders, Pneumonia.
- statistics & numerical data : Mass Vaccination.
- Aged, Aged, 80 and over, Case-Control Studies, Hospitalization, Humans, Risk Factors.
Abstract
Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case-control studies were performed during the 2004-2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n=105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for pneumonia. The risk of hospitalisation after the start of the influenza season was significantly lower in vaccinated patients compared with non-vaccinated patients (adjusted odds ratios: 0.13 [P=0.013] for ACS; 0.07 [P=0.007] for CVA; 0.31 [P=0.005] for pneumonia). During peak virus circulation, vaccination with MF59-adjuvanted subunit influenza vaccine was associated with an 87% relative risk reduction in hospitalisation for ACS, 93% for CVA, and 69% for pneumonia.
DOI: 10.1016/j.vaccine.2007.08.039
PubMed: 17889411
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.</title><author><name sortKey="Puig Barbera, Joan" sort="Puig Barbera, Joan" uniqKey="Puig Barbera J" first="Joan" last="Puig-Barberà">Joan Puig-Barberà</name><affiliation wicri:level="1"><nlm:affiliation>Fundación de la Sociedad Valenciana de Medicina de Familia y Comunitaria, Valencia, Spain. jpuigb@terra.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Fundación de la Sociedad Valenciana de Medicina de Familia y Comunitaria, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Diez Domingo, Javier" sort="Diez Domingo, Javier" uniqKey="Diez Domingo J" first="Javier" last="Díez-Domingo">Javier Díez-Domingo</name></author><author><name sortKey="Varea, Angel Belenguer" sort="Varea, Angel Belenguer" uniqKey="Varea A" first="Angel Belenguer" last="Varea">Angel Belenguer Varea</name></author><author><name sortKey="Chavarri, German Schwarz" sort="Chavarri, German Schwarz" uniqKey="Chavarri G" first="Germán Schwarz" last="Chavarri">Germán Schwarz Chavarri</name></author><author><name sortKey="Rodrigo, Jose A Lluch" sort="Rodrigo, Jose A Lluch" uniqKey="Rodrigo J" first="José A Lluch" last="Rodrigo">José A Lluch Rodrigo</name></author><author><name sortKey="Hoyos, Santiago Perez" sort="Hoyos, Santiago Perez" uniqKey="Hoyos S" first="Santiago Pérez" last="Hoyos">Santiago Pérez Hoyos</name></author><author><name sortKey="Vidal, David Gonzalez" sort="Vidal, David Gonzalez" uniqKey="Vidal D" first="David González" last="Vidal">David González Vidal</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17889411</idno><idno type="pmid">17889411</idno><idno type="doi">10.1016/j.vaccine.2007.08.039</idno><idno type="wicri:Area/Main/Corpus">00554</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">00554</idno><idno type="wicri:Area/Main/Curation">000554</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000554</idno><idno type="wicri:Area/Main/Exploration">000554</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.</title><author><name sortKey="Puig Barbera, Joan" sort="Puig Barbera, Joan" uniqKey="Puig Barbera J" first="Joan" last="Puig-Barberà">Joan Puig-Barberà</name><affiliation wicri:level="1"><nlm:affiliation>Fundación de la Sociedad Valenciana de Medicina de Familia y Comunitaria, Valencia, Spain. jpuigb@terra.es</nlm:affiliation><country xml:lang="fr">Espagne</country><wicri:regionArea>Fundación de la Sociedad Valenciana de Medicina de Familia y Comunitaria, Valencia</wicri:regionArea><wicri:noRegion>Valencia</wicri:noRegion></affiliation></author><author><name sortKey="Diez Domingo, Javier" sort="Diez Domingo, Javier" uniqKey="Diez Domingo J" first="Javier" last="Díez-Domingo">Javier Díez-Domingo</name></author><author><name sortKey="Varea, Angel Belenguer" sort="Varea, Angel Belenguer" uniqKey="Varea A" first="Angel Belenguer" last="Varea">Angel Belenguer Varea</name></author><author><name sortKey="Chavarri, German Schwarz" sort="Chavarri, German Schwarz" uniqKey="Chavarri G" first="Germán Schwarz" last="Chavarri">Germán Schwarz Chavarri</name></author><author><name sortKey="Rodrigo, Jose A Lluch" sort="Rodrigo, Jose A Lluch" uniqKey="Rodrigo J" first="José A Lluch" last="Rodrigo">José A Lluch Rodrigo</name></author><author><name sortKey="Hoyos, Santiago Perez" sort="Hoyos, Santiago Perez" uniqKey="Hoyos S" first="Santiago Pérez" last="Hoyos">Santiago Pérez Hoyos</name></author><author><name sortKey="Vidal, David Gonzalez" sort="Vidal, David Gonzalez" uniqKey="Vidal D" first="David González" last="Vidal">David González Vidal</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Cardiovascular Diseases (epidemiology)</term><term>Cardiovascular Diseases (prevention & control)</term><term>Case-Control Studies (MeSH)</term><term>Cerebrovascular Disorders (epidemiology)</term><term>Cerebrovascular Disorders (prevention & control)</term><term>Hospitalization (MeSH)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Mass Vaccination (statistics & numerical data)</term><term>Pneumonia (epidemiology)</term><term>Pneumonia (prevention & control)</term><term>Polysorbates (administration & dosage)</term><term>Risk Factors (MeSH)</term><term>Spain (epidemiology)</term><term>Squalene (administration & dosage)</term><term>Vaccines, Subunit (administration & dosage)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Angiopathies intracrâniennes (prévention et contrôle)</term><term>Angiopathies intracrâniennes (épidémiologie)</term><term>Espagne (épidémiologie)</term><term>Facteurs de risque (MeSH)</term><term>Hospitalisation (MeSH)</term><term>Humains (MeSH)</term><term>Maladies cardiovasculaires (prévention et contrôle)</term><term>Maladies cardiovasculaires (épidémiologie)</term><term>Pneumopathie infectieuse (prévention et contrôle)</term><term>Pneumopathie infectieuse (épidémiologie)</term><term>Polysorbates (administration et posologie)</term><term>Squalène (administration et posologie)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Vaccination de masse (statistiques et données numériques)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins sous-unitaires (administration et posologie)</term><term>Études cas-témoins (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term><term>Polysorbates</term><term>Squalene</term><term>Vaccines, Subunit</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Spain</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Polysorbates</term><term>Squalène</term><term>Vaccins antigrippaux</term><term>Vaccins sous-unitaires</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Cardiovascular Diseases</term><term>Cerebrovascular Disorders</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Cardiovascular Diseases</term><term>Cerebrovascular Disorders</term><term>Pneumonia</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Angiopathies intracrâniennes</term><term>Maladies cardiovasculaires</term><term>Pneumopathie infectieuse</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Mass Vaccination</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Vaccination de masse</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Angiopathies intracrâniennes</term><term>Espagne</term><term>Maladies cardiovasculaires</term><term>Pneumopathie infectieuse</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Case-Control Studies</term><term>Hospitalization</term><term>Humans</term><term>Risk Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Facteurs de risque</term><term>Hospitalisation</term><term>Humains</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Études cas-témoins</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Espagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case-control studies were performed during the 2004-2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n=105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for pneumonia. The risk of hospitalisation after the start of the influenza season was significantly lower in vaccinated patients compared with non-vaccinated patients (adjusted odds ratios: 0.13 [P=0.013] for ACS; 0.07 [P=0.007] for CVA; 0.31 [P=0.005] for pneumonia). During peak virus circulation, vaccination with MF59-adjuvanted subunit influenza vaccine was associated with an 87% relative risk reduction in hospitalisation for ACS, 93% for CVA, and 69% for pneumonia.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17889411</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>42</Issue><PubDate><Year>2007</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.</ArticleTitle><Pagination><MedlinePgn>7313-21</MedlinePgn></Pagination><Abstract><AbstractText>Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case-control studies were performed during the 2004-2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n=105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for pneumonia. The risk of hospitalisation after the start of the influenza season was significantly lower in vaccinated patients compared with non-vaccinated patients (adjusted odds ratios: 0.13 [P=0.013] for ACS; 0.07 [P=0.007] for CVA; 0.31 [P=0.005] for pneumonia). During peak virus circulation, vaccination with MF59-adjuvanted subunit influenza vaccine was associated with an 87% relative risk reduction in hospitalisation for ACS, 93% for CVA, and 69% for pneumonia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Puig-Barberà</LastName><ForeName>Joan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Fundación de la Sociedad Valenciana de Medicina de Familia y Comunitaria, Valencia, Spain. jpuigb@terra.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díez-Domingo</LastName><ForeName>Javier</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Varea</LastName><ForeName>Angel Belenguer</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Chavarri</LastName><ForeName>Germán Schwarz</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Rodrigo</LastName><ForeName>José A Lluch</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Hoyos</LastName><ForeName>Santiago Pérez</ForeName><Initials>SP</Initials></Author><Author ValidYN="Y"><LastName>Vidal</LastName><ForeName>David González</ForeName><Initials>DG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C089950">MF59 oil emulsion</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011136">Polysorbates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022223">Vaccines, Subunit</NameOfSubstance></Chemical><Chemical><RegistryNumber>7QWM220FJH</RegistryNumber><NameOfSubstance UI="D013185">Squalene</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032541" MajorTopicYN="N">Mass Vaccination</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="N">Pneumonia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011136" MajorTopicYN="N">Polysorbates</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013185" MajorTopicYN="N">Squalene</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D022223" MajorTopicYN="N">Vaccines, Subunit</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>08</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>9</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>9</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17889411</ArticleId><ArticleId IdType="pii">S0264-410X(07)00975-9</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2007.08.039</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Espagne</li></country></list><tree><noCountry><name sortKey="Chavarri, German Schwarz" sort="Chavarri, German Schwarz" uniqKey="Chavarri G" first="Germán Schwarz" last="Chavarri">Germán Schwarz Chavarri</name><name sortKey="Diez Domingo, Javier" sort="Diez Domingo, Javier" uniqKey="Diez Domingo J" first="Javier" last="Díez-Domingo">Javier Díez-Domingo</name><name sortKey="Hoyos, Santiago Perez" sort="Hoyos, Santiago Perez" uniqKey="Hoyos S" first="Santiago Pérez" last="Hoyos">Santiago Pérez Hoyos</name><name sortKey="Rodrigo, Jose A Lluch" sort="Rodrigo, Jose A Lluch" uniqKey="Rodrigo J" first="José A Lluch" last="Rodrigo">José A Lluch Rodrigo</name><name sortKey="Varea, Angel Belenguer" sort="Varea, Angel Belenguer" uniqKey="Varea A" first="Angel Belenguer" last="Varea">Angel Belenguer Varea</name><name sortKey="Vidal, David Gonzalez" sort="Vidal, David Gonzalez" uniqKey="Vidal D" first="David González" last="Vidal">David González Vidal</name></noCountry><country name="Espagne"><noRegion><name sortKey="Puig Barbera, Joan" sort="Puig Barbera, Joan" uniqKey="Puig Barbera J" first="Joan" last="Puig-Barberà">Joan Puig-Barberà</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeEspagneV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000574 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000574 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeEspagneV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:17889411
|texte= Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:17889411" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeEspagneV1
| This area was generated with Dilib version V0.6.37. |  |